719 / 1631
Landmark (from EOI) PFS analysis:
by antibody arm
1.0
0.8
0.6
0.4
0.2
0
0
6
12
18
24
30
36
42
48
54
Time since end of treatment (months)
Probability
R-CMR (n=217)
G-CMR (n=232)
R non-CMR (n=34)
G non-CMR (n=25)
Censored
PFS for non-CMR vs CMR status using Lugano 2014 criteria (N=508)
R-CMR, n=217
G-CMR, n=232
R non-CMR, n=34
G non-CMR, n=25
2.5-year PFS from EOI, % (95%
CI)
85.7
(79.4, 89.4)
89.5
(84.5, 93.0)
41.4
(23.2, 58.8)
69.7
(46.5, 84.3)
HR (95% CI)
0.7 (0.4, 1.0); p=0.06
0.5 (0.2, 1.2); p=0.10
89.5 (84.5, 93.0)
85.7 (79.4, 89.4)
41.4 (23.2, 58.8)
69.7 (46.5, 84.3)
Trotman J, et al. ICML 2017